Introduction
Leukaemias, and in particular myeloid leukaemias, are the most common malignancies associated with accidental, occupational or therapeutic exposure to ionising radiation. 1 It is generally accepted that the major effect of radiation exposures is the initiation of malignant change, rather than promotional effects on pre-existing initiated cells; however, this should not be interpreted to mean that radiation has no part to play in other aspects of the development of malignant disease. 2 Although relatively little is known about the molecular mechanism(s) by which ionising radiation initiates leukaemic transformation, the early events impart to the target cell a proliferative and/or survival advantage. Human de novo acute leukaemias are characterised by non-random chromosomal translocations giving rise to fusion genes encoding oncogenic proteins, 3, 4 although they may also exhibit inactivated tumour suppressor genes. 5, 6 Secondary acute myeloid leukaemia (AML) evolving from previous myelodysplastic syndrome (MDS) or developing after exposure to radiotherapy and/or certain chemotherapeutic agents, in contrast to de novo AML, is characterised cytogenetically by chromosomal deletion, often involving one of the homologues of chromosome 5 or 7. 7 This chromosomal loss is presumably associated with tumour suppressor gene inactivation although the genes involved are yet to be identified. The incidence of secondary leukaemia is predicted to increase in developed countries because of the inevitable increase in MDS associated with an ageing population and the widespread and successful use of aggressive radio/chemotherapy. Hence, understanding the mechanism(s) leading to the transformation of the target stem cells, as well as the specific nature and consequences of the molecular changes associated with the leukaemogenic process is important both for mechanistic understanding and potential therapeutic intervention. Studying the earliest events in human leukaemias is generally not possible and animal models are necessary to investigate the types of lesions involved in leukaemia initiation. Mice provide particularly useful experimental models due to the similarity of the essential features of haemopoiesis in mice and humans and the potential for genetic investigations. Numerous studies have demonstrated genotype-dependent responses to irradiation but in the majority of cases the resulting tumours are thymic lymphomas. However, AML may be induced by radiation in certain inbred strains of mice such as RFM, CBA/H, CBA/Ca, SJL/J and C3H/He strains. [8] [9] [10] [11] [12] In many studies, the CBA strains have proved of particular value due to the very low spontaneous incidence and the reproducible induction of AML in 20-25% of animals following a single acute exposure to 3 Gy total body X-irradiation. 10, [12] [13] [14] Analyses of the radiation-induced AMLs in the mouse models have identified deletion involving one homologue of chromosome 2 (chr 2) as a characteristic feature. 12, [15] [16] [17] More than 90% of the leukaemias examined cytogenetically exhibit this chr 2 loss in the C to F regions. 18 Molecular genetic studies of F1 hybrid mice have confirmed region-specific loss of heterozygosity (LOH) in genetically linked set of markers from one homologue of chr 2 and defined a common minimally deleted region (MDR) of 1 cM on chr 2, localised at about 50 cM between two polymorphic microsatellite markers D2MIT126 and D2MIT185. 18, 19 Recent studies of LOH in radiation-induced leukaemias have demonstrated that up to 75% of radiation-induced AMLs, but not thymic lymphomas in (CBA/H × C57BL/6) F1 mice exhibit chr 2 LOH 20 and up to 20% LOH can be observed for many other chromosomal regions. 20, 21 LOH incidences of less than 20% have been interpreted to have a non-causal role and considered to be secondary non-specific events incidentally arising during leukaemia development. This high frequency of the characteristic chr 2 LOH in radiation-induced AML suggests a potentially causal role for this event. However, frank leukaemia cells are not the most suitable material to dissect early and potentially initiating events in the target stem cells. In recognition of this, bone marrow obtained from irradiated mice or from mice transplanted with irradiated bone marrow has been investigated cytogenetically. Aberrations involving chromosome 2 have been detected 3-21 days post-transplantation of in vitro irradiated bone marrow in the donor cells 22 and in bone mar-row obtained from irradiated mice at times significantly before the first appearance of AML. 23 Whilst, neither the induction of a chr 2 aberration nor the presence of a chr 2 aberrant clone specifically predict the development of AML in an individual irradiated mouse, 23 these data have been interpreted as the chr 2 deletion being an early and possibly initiating event in radiation-induced AML.
It is widely accepted that leukaemia development is a multistep process originating in the stem cell compartment, that stem cells constitute a minority population in the bone marrow, that only a few stem cells contribute to haemopoiesis at one time and that different clones are active at different times in the life span of an organism. All the studies noted above used total bone marrow consisting of a mixture of cell types at all stages of differentiation and maturity. Thus, these studies have not specifically addressed the question of whether chr 2 aberrations are present at a high frequency in stem cells and are induced directly by the irradiation or arise indirectly as a consequence of radiation-induced chromosomal instability. 24 We have conducted experiments to test the hypothesis that LOH involving chr 2 is induced in haemopoietic stem cells as a direct consequence of the radiation exposure. For this purpose, we have studied the induction of LOH at the defined minimally deleted region on chr 2 in the progeny of (CBA/H × C57BL/6) F1 haemopoietic stem cells after a single acute exposure of 3 Gy X-irradiation in vitro. This has been achieved by developing a polymerase chain reaction (PCR)-based method for detecting LOH, using polymorphic microsatellite markers, in colonies derived from irradiated and unirradiated clonogenic cells originating from the same pooled bone marrow samples. The analysis suggest that chr 2 LOH induced directly by irradiation may not be as high a frequency event in long-term repopulating stem cells as might be inferred from previous cytogenetic studies.
Materials and methods

Mice and cells
CBA/H, C57BL/6 and (CBA/H × C57BL/6) F1 mice were bred in the MRC unit. Total bone marrow for in vitro or in vivo clonogenic assays and transplantation studies was obtained from male (CBA/H × C57BL/6) F1 mice, and female CBA/H mice were used as transplantation recipients. Total genomic DNA (gDNA) used as control and also to perform preliminary experiments was extracted from tails or spleens of CBA/H, C57BL/6 or (CBA/H × C57BL/6) F1 mice. Similarly, total bone marrow necessary for mixing or background experiments was also collected from the same strains. All animal experimentations were conducted under guidance issued by the MRC in 
Experimental protocol
Femoral bone marrow was obtained from 8-to 12-week-old male (CBA/H × C57BL/6) F1 mice. One aliquot was retained as an unirradiated control and one aliquot exposed to 3 Gy Xrays at 0.5 Gy/min using a Siemens Stabiliplan X-ray machine operating at 250 kV constant potential and 14 mA, giving Xrays with a half value layer of 1.1 mm of copper. The two
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Figure 1
Experimental protocol designed to investigate the frequency with which LOH involving chr 2 at the defined MDR and other genomic regions is induced in haemopoietic stem cells as a direct consequence of a single exposure to 3 Gy X-irradiation. Pooled bone marrow obtained from 20 (CBA/H × C57BL/6) F1 donors was irradiated and samples used to generate colonies in vitro and in vivo using clonogenic assays. Aliquots of pooled bone marrow containing 200 CFU-S were transplanted into each of 20 recipients. At 20, 30 and 120 days post-transplantation, bone marrow was collected from three recipients and pooled to generate colonies in vitro and in vivo. The progeny of clonogenic cells present in the irradiated pooled bone marrow and in the bone marrow obtained from the transplanted recipients was investigated for LOH using a PCR-based method to detect polymorphic microsatellite markers. Concurrent controls were similarly investigated. pools of bone marrow (irradiated and control) were then investigated in parallel using the protocol shown in Figure 1 .
The analysis of short-term repopulating stem cells was performed using two previously described clonogenic assays, the in vitro CFU-A assay 25 and in vivo CFU-S assay. 26 These assays were used to analyse colonies derived from irradiated or control bone marrow clonogenic cells immediately after irradiation and from repopulating bone marrow 20 and 30 days post-transplantation. They were also used to analyse the descendants of stem cells present in bone marrow repopulated by irradiated long-term repopulating stem cells by assaying the bone marrow at 120 days post-transplantation. For each time point, femoral bone marrow was obtained from three mice transplanted with irradiated or non-irradiated cells. LOH analyses were performed by PCR amplification of known polymorphic microsatellite markers localised on four different chromosomes (2, 4, 11, and 14) using total gDNA extracted from the various colonies derived.
Figure 2
Kination of PCR product for D2MIT185, aliquots of PCR reactions were incubated in presence of (␥-32 P)-ATP and 2.5 U of T4 polynucleotide kinase, then resolved by denaturing polyacrylamide gel electrophoresis and autoradiography. 
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Clonogenic assay CFU-A assays:
The CFU-A assay was used to obtain clones of cells in vitro derived from members of the shortterm repopulating haemopoietic stem cell compartment. Cells were plated in 45-mm Petri dishes (Sterilin, Stone, UK) containing 2 ml modified alpha Eagle's medium (Gibco BRL, Life Technologies, Paisley, UK) supplemented with 20%, pretested horse serum (Sera-Lab, Crawley Down, UK), 0.3% low melting point agarose (Gibco BRL, Life Technologies, Paisley, UK) and conditioned media from the AF1.19T and L929 cell lines batch-tested to provide maximal colony-stimulating activities as previously described. 27 The amount of total irradiated and unirradiated bone marrow cells plated was calculated to generates five to 10 isolated CFU-A per dish, and at least a total of 100 colonies per time point. CFU-A-derived clones were individually collected using plastic disposable pipettes under inverted microscope, in sterile Eppendorf tubes containing 100 l of lysis buffer (10 mm Tris-HCl pH 8, 0.5 mm EDTA and 1% (w/v) N-lauryl sarcosyl) 28 after 10 to 13 days incubation and kept at 4°C until gDNA extraction.
CFU-S assays:
The CFU-S assay was used to obtain clones of cells in vivo derived from members of the short-term repopulating haemopoietic stem cell compartment. Colonies were generated by injecting unirradiated or irradiated cells into CBA/H female recipient mice irradiated 1 h previously with 8.2 Gy X-rays. The amount of total irradiated and unirradiated bone marrow cells injected was calculated to generate five to eight isolated CFU-S per mouse spleen, and at least a total of 50 colonies per time point. Individual spleen colonies were then collected at 8 and/or 11 days post-injection, snap-frozen in liquid nitrogen and kept at −20°C until total gDNA extraction was performed.
Genomic DNA extraction
Total gDNA was extracted from CFU-S (8 or 11 days) or CFU-A colonies according to established protocols. 29 In short, collected clones kept frozen or at 4°C in lysis buffer were treated with protease K overnight at 42°C (Pharmacia, Amersham, UK) then by ribonuclease A (Gibco BRL, Life Technologies) for 1 h at 37°C; extracted with phenol and phenol-chloroform at pH 8 (Sigma, St Louis, USA) and precipitated with sodium acetate 0.3 m final concentration at pH 5.2 and isopropanol. The precipitate was collected by an ultra-centrifugation (Beckman, High Wycombe, UK) at 4°C for 30 min at 30 000 g then resuspended in 10 l of TE 1/0.1 buffer (1 mm TrisHCl, 0.1 mm EDTA pH 8) and allowed to redissolve at room temperature. After extraction total gDNA were stored at 4°C in TE 1/0.1 buffer until use. Total gDNA from tail and spleen was extracted essentially as described in Ref. 30 and kept at 4°C.
Microsatellite markers amplification and kinase reaction
Microsatellite marker amplifications were performed by PCR according to established protocols 31 using either 100 ng (CFU-S) or 10 ng (CFU-A) of total gDNA as template, in a total volume of 10 l. PCR were performed using 0. 32 used for chr 4 were purchased from Genosys Sigma (Cambridge, UK). Additional sets of primers used to analyse further the extent of LOH on chr 2 were also purchased from Research Genetics Inc. A final concentration of 0.5 m in the PCR reaction was used for all microsatellite primer pairs and their respective sequences can be found at the Whitehead Institute's mouse physical database at http://www-genome.wi.mit.edu/egibin/mouse/index. All PCR runs contained a blank negative, as well as positive reactions, respectively, using homozygous CBA/H, C57BL/6 and heterozygous F1 gDNA as controls. PCR products were visualised by UV transillumination after electrophoresis on a 3% (w/v) agarose gel in 1 × TBE buffer (90 mm Tris-borate, 2 mm EDTA) containing ethidium bromide (0.5 g/ml).
Kination of the PCR product ( Figure 2 ); 3 l of PCR reaction (25/28/30 cycles) were incubated at 37°C for 30 min in 10 l final volume of a solution containing 50 mm Tris-HCl pH 7.6, 100 mm MgCl 2 , 5 mm dithiothreitol, 2 Ci (gamma-32 P)-dATP (3000 Ci/mmol, Amersham) and 2.5 U of T4 polynucleotide kinase (Gibco BRL, Life Technologies). The reaction was stopped by addition of three volumes of a 90% formamide solution. Products were resolved by denaturing 6% (w/v) polyacrylamide gel electrophoresis and autoradiography.
LOH was recorded for each colony and frequencies analysed using the Fisher's exact test.
Results
Validation experiments
Quality and quantity of gDNA extracted from clonogenic cells:
Extraction tests were performed to assess the quantity and quality of gDNA that could be routinely obtained from either CFU-S-derived clones or CFU-A-derived clones containing of the order of 4-5 × 10 5 cells per CFU-S colonies (day 11) and 5 × 10 4 cells per CFU-A colony (days 11-13). The quality of the gDNA extracted was assessed by running 1 l of gDNA in a 0.6% agarose gel in 1 × TBE to check for the integrity of DNA visualised as high molecular weight product without visible laddering/smearing in the low molecular weight range, as well as the absence of contaminating RNA. The concentration of gDNA in each sample was ascertained by UV spectrophotometry (260 nm) and by running fixed amounts of each sample in parallel with DNA standards of known concentration in a 0.8% agarose 1 × TBE gel. On average the amount of gDNA obtained routinely for in vivo CFU-S-derived clones was Ͼ1 g, and 80 to 150 ng for in vitro CFU-A-derived clones. The addition of tRNA as carrier to the isopropanol precipitation did not clearly improve the gDNA yield recovery. Overall, the gDNA was considered to be of good quality and on a regular basis, the amount of gDNA extracted from in vitro clones allowed us to perform six to 10 PCR reactions per clone and the larger quantity obtained from in vivo clones did not present any limitations for our PCR analyses.
Validation of the polymorphic microsatellite markers analyses by preliminary studies:
The validation of the technical protocol was obtained through a set of several preliminary experiments: identification of microsatellite markers, optimisation of PCR assays, evaluation of background contamination, mixing experiment and titration curve.
(1) Identification of informative microsatellite polymorphisms:
Microsatellite markers were selected from the mouse Map Pairs database (see Materials and methods) on the basis of published allelic size difference between CBA/H or C3H (a close relative of CBA/H) and C57BL/6 alleles, and microsatellite markers available throughout the literature. They are indicated in Table 1 along with their localisation; also potential genes of interest present in close vicinity are indicated, as well as the corresponding human syntenic region. Additional microsatellite markers were used to assess the extent of the deleted area in the specific case of one day 8 CFU-S colony displaying LOH at D2MIT185, they are D2MIT237, D2MIT280 and D2MIT311 localised respectively at 23.7, 66.7 and 83.1 cm. The chr 2 LOH in this clone was confirmed by kination ( Figure 2 , lane 8), there was no LOH for any of the three other chromosomal regions analysed, all of which exhibited heterozygosity for the microsatellite markers used (see above). (2) Optimisation of the PCR assays: The sensitivity and specificity of the PCR amplification reactions were optimised individually for each microsatellite marker tested using control gDNA extracted from tail or spleen of CBA/H, C57BL/6 and (CBA/H × C57BL/6) F1 mouse. Only the unambiguously proven polymorphic markers between CBA/H and C57BL/6 strain with our PCR conditions were retained for further use. All PCR runs contained a blank negative, as well as positive controls consisting of gDNA extracted from tail or spleen obtained from parental homozygous CBA/H, C57BL/6 and heterozygous F1 mice. Gen- 18 is localised between 49.3 and 54.5 cM on the murine chromosome 2, this region includes small section of synteny with human chromosome 1q, 2q, 15q but the majority of this area is syntenic with chromosome 11p13-14. WT1, Wilms tumour; Rb, retinoblastoma. Leukemia omic DNA concentration (100 or 10 ng) and number of cycles (30 or 40) performed in control PCRs were matched to the same parameters in the test reactions. Amplifications of gDNA from coded samples of known radiationinduced leukaemias displaying LOH at one of the four chosen polymorphic microsatellite markers or no LOH (kindly provided by H Cleary, MRC Unit, Harwell, Didcot, UK) were performed to confirm the reliability of our PCR assays. (3) Mixing experiment: The specificity of the in vitro clonogenic assays was tested by separately collecting total bone marrow cells respectively from CBA/H or C57BL/6 mice and then mixing them at appropriate concentrations to perform the CFU-A clonogenic assay. Clones were collected, gDNA extraction and PCR reactions for the four microsatellite markers were performed. All samples showed only one band confirming that no colony was generated from more than one clonogenic cell. (4) Background contamination: To test for background contamination in in vitro assays, agarose containing media from inter-colony regions in Petri dishes was collected at each time point of the analysis and treated as samples (meaning gDNA extraction was performed followed by PCR). Contamination by cells, small clusters or cellular debris was found to be minimal as no PCR product could be detected in these conditions. Contamination by host spleen tissue is a potential complication for the LOH analyses of CFU-S-derived colonies as it may mask LOH. Interference by host tissue was unambiguously detected when spleen colonies were dissected to deliberately include additional splenic tissue (ෂ20%). Host spleen tissue contamination only arose in subsequent experiments for a few of the smaller days 8 CFU-S-derived colonies and was readily identified by the fact that the contaminated clones displayed LOH for the C57BL/6 allele at all four chromosomes analysed. The overall host spleen tissue contamination frequency was found to be 7.2 and 10.5%, respectively, in controls (n = 42) and day 8 CFU-S-derived colonies (n = 46). These clones were excluded from the final data analysis. No host spleen tissue contamination was found for any of the day 11 CFU-S-derived clones analysed. (5) Titration curve: Preliminary PCR titration studies were carried out using increasing amount of either CBA/H or C57BL/6 gDNA to check for equal amplification of the two alleles during the PCR as it been reported 33, 34 that PCR amplification of some microsatellite markers would not yield equal amplification of the two alleles. This bias towards a stronger amplification of one allele can lead to misinterpretation (ie scoring of allelic imbalance) when gDNA concentration is very low or suboptimal PCR conditions are used. To investigate this potential problem we performed PCR using inversely varying concentrations of the two parental gDNAs in a set of reactions.
The gDNA mixes used were 100/0, 90/10, 80/20, 60/40, 50/50, 40/60, 20/80, 10/90, 0/100% of CBA/H and C57BL/6 homozygous gDNA. The titration curves were performed for each of the four microsatellite markers used and repeated for 30 and 40 cycle PCR reactions corresponding to 100 or 10 ng, respectively, of gDNA (data not shown). Using 30 or 40 cycles, for D2MIT185, a 60% concentration of the CBA allele was necessary for reliable detection; in contrast only a 20% contribution of the C57BL/6 allele was necessary. Thus, the C57BL/6 allele is preferentially amplified and consequently detected with much greater sensitivity than the CBA/H allele. Similar data were obtained for all four microsatellite markers tested. These findings precluded consideration of any potential allelic imbalance, strictly restricted all scoring of LOH to unambiguous PCR products and required confirmation by a kinase reaction of the PCR product (from a second independent run) for all clones showing LOH.
Analysis of radiation-induced LOH LOH observed in clonogenic assays performed immediately after bone marrow irradiation:
No LOH was detected in 251 control colonies and few (0-2.4%) in vitro or in vivo colonies demonstrated radiation-induced LOH at any of the four chromosomal regions analysed ( Table 2) . With respect to the chr 2 region characteristically deleted in radiation-induced AMLs, only two clones of the 297 tested (0.7%) demonstrated LOH, 1/42 day 8 CFU-S-derived colonies and 1/173 day 11 CFU-A-derived colonies. The only positive CFU-S-derived clone was further analysed and the deleted area was more precisely assessed by using additional polymorphic microsatellite markers; these demonstrated no LOH, confirming that the deleted area was restricted to the chr 2 MDR. Overall, chr 2 LOH was not detected at a greater frequency than LOH at the other regions (P = 0.3136, P = 0.2496, P = 0.3593, localised on chromosomes 4, 11 and 14, respectively).
LOH observed in clonogenic assays established from transplanted animals:
No LOH was detected in 100 control colonies and of the 403 colonies derived from CFU-A obtained from bone marrow 20 or 30 days post-transplantation 9 (2.2%) exhibited LOH on chr 2. However, all nine positive colonies were detected in the original experiment in which 110 clones were examined indicating that 8.2% of these CFU-A-derived clones exhibited LOH in this region; a second independent experiment in which 143 clones were examined found no LOH in this region ( Table 2 ). The very high frequency observed in the first cohort was not detected at the later sampling time of 120 days (1/135 positive clones) and was not detected in the CFU-S-derived colonies 30 or 120 days post-transplantation. Thus, a significantly greater frequency of chr 2 LOH was demonstrated in short-term repopulation compared with long-term repopulation (P = 0.0864). Comparing the early with the late repopulation, there was no significant difference in LOH at other chromosomal regions (P = 0.4444, P = 0.4455, P = 0.4490 for chromosome 4, 11 and 14, respectively).
In the early phase of repopulation (20-30 days posttransplantation) no LOH was detected in 142 control colonies and 432 clones derived from recipients of irradiated bone Table 2 LOH identified in the progeny of 3 Gy X-irradiated bone marrow clonogenic cells marrow were examined (Table 3 ). The 2.1% frequency of chr 2 LOH was significantly greater than LOH at chromosomal regions 4 (0.2%) and 11 (0.5%) (P = 0.0094, P = 0.0263, respectively), but not greater than the 0.9% for chr 14 (P = 0.2634). In the long-term reconstituted bone marrow assayed at 120 days post-transplantation, LOH on chr 2 was not greater than in any other region (P = 0.5011, P = 0.5000, P = 0.6143, comparing chr 2 with chr 4, 11 and 14, respectively). Considering all the examples of LOH detected in this study, the chr 2 LOH demonstrated a highly significant strain bias as all of the 11 deleted regions were CBA/H (Table 4) . For chromosomal regions 4, 11 and 14, the CBA/H loss was 3/5, 0/2 and 1/3, respectively.
Discussion
Deletions of one homologue of chr 2 are characteristic of radiation-induced AMLs in mouse models 12, [15] [16] [17] and a number of cytogenetic studies have demonstrated that a variety of chr 2 aberrations can be detected in the bone marrow of irradiated mice many months before overt leukaemia and in the bone marrow of mice transplanted with irradiated bone marrow. One of the early studies by Haran-Ghera and colleagues 23 demonstrated that 2 to 75% of analysed metaphases exhibited chr 2 aberrations in at least 80% of SJL/J mice examined 4 months after whole body irradiation exposure. Noting the discrepancy with the lower (20-25%) leukaemia incidence, they concluded that chr 2 deletion appeared to be necessary, but not sufficient, to cause overt AML development. 23 A similar but more detailed time course study 17 demonstrated chr 2 aberrations in 20 to 24% of irradiated CBA/Ca mice from 20 h to 24 months. The data were consistent with an abnormal haematological or histological phenotype only being detected in mice with at least 30% of cells having an abnormal chr 2. However, the majority of the chr 2 aberrations detected in this study were translocations suggesting that aberrations other than deletions may be important in the development of radiation-induced AMLs and may also reflect the initiating lesion. The authors suggested that haemopoietic precursor cells with translocations involving chr 2 had an initial proliferative advantage, but limited proliferative capacity and as these cells died out they were replaced by potentially leukaemic cells with the chr 2 deletion. Whilst, late appearing cells with a chr 2 deletion induced directly by irradiation cannot be excluded, it was suggested that the disappearance of the translocations and subsequent appearance of deletions might be associated with chromosomal instability. Evidence consistent with this suggestion is provided by an independent study describing a radiation-induced AML in which a terminal translocation evolved into an interstitial deletion. 35 High frequencies of radiation-induced translocations and Table 3 LOH identified in the progeny of clonogenic cells obtained from repopulated bone marrow after transplantation of 3 Gy X-irradiated bone marrow
Colony type
Number of clones exhibiting LOH in 4 chromosomal regions (%) deletions involving chr 2 have been demonstrated using a bone marrow transplantation protocol, 16 in which 106 chromosomally abnormal clones were identified in 29 CBA/H recipients of 3 Gy X-irradiated bone marrow. The frequency of aberrant cells was reported to be approximately 30% of all metaphases between 5 and 35 days post-transplantation, but fell to 5-10% after 80 days. Of these clones, 31/106 (29%) involved chromosome 2 leading to the suggestion that chr 2 aberrations were early and potentially initiating events for radiation-induced AMLs and that chr 2 breakage was associated with radiation-sensitive site. 36 However, because most of the chr 2 aberrations declined in the early phase of repopulation and as bone marrow contains a wide range of proliferating cell types, the data are not informative as to whether any chr 2 deletions were directly induced at high frequency in irradiated long-term repopulating stem cells.
In a subsequent study 35 of 651 bone marrow metaphases obtained from 20 CBA/H mice at 1, 3 and 6 months after 3 Gy whole body X-irradiation, all mice were reported to carry at least one chromosome 2 aberration (translocations and deletions). As chr 2 aberrations were detected in all the irradiated mice, the formation of such aberrations clearly is not predictive of the expected 20% leukaemia development in this mouse strain; a finding consistent with the conclusion of the earlier study of irradiated SJL/J mice. 23 Of the 11 chr 2 interstitial deletions recorded, nine were similar in terms of breakpoint locations previously reported for the characteristic lesion in AMLs, but there was no evidence that these cells demonstrated any proliferative advantage. A more detailed study of chr 2 aberrations after 3 Gy whole body X-irradiation in an independent strain of CBA/H mice using chromosome painting 37 demonstrated only approximately two-fold greater frequency in aberrations involving chr 2 than chrs 1 and 3 at Leukemia 24 h and 48 h post-irradiation. For the inclusive period of 1-15 months in 32 mice examined, no leukaemias were detected, but clonal translocations and deletions were observed in all animals (an average of 0.31 clones per mouse) and more than half of these clones involved chr 2. With time, the frequency of mice in which cytogenetically aberrant clones were detected increased, a phenomenon that would be conventionally attributed to delayed recruitment into proliferation of radiation-damaged cells but, given the observations of Rithidech and colleagues, 17 the subclonal aberrations detected in AMLs induced in the Japanese bomb survivors 38 and the growing evidence for delayed responses to irradiation, 39 radiation-induced chromosomal instability 24 may well be a contributory factor. Using a molecular approach, we have now demonstrated that exposing mouse bone marrow in vitro to a potentially leukaemogenic dose of X-irradiation resulted in the induction of LOH in the region of chr 2 characteristically deleted in radiation-induced AMLs in 2/297 (0.7%) clonogenic multipotential short-term repopulating stem cells (Table 2) . However, this frequency is not greater than the detected frequency of LOH in the other chromosomal regions studied. For example, a region of chr 14, not reported to be deleted by cytogenetic studies of any radiation-induced leukaemias, exhibited a similar induction of LOH (2/219, ie 0.9%). The detection of LOH in 8% of colonies derived from the CFU-A compartment in the repopulating bone marrow 30 days post-transplantation (Table 3) in one experiment seems a fortuitous finding but direct evidence of multipotential stem cells exhibiting such LOH being able to proliferate in vivo. Clearly, the data obtained in this molecular study, together with the cytogenetic investigations, [15] [16] [17] [18] provide evidence that radiation-induced abnormalities of chromosome 2, including deletions in the region commonly deleted in radiation-induced AMLs, can be detected in clonogenic cells. However, the failure to deleted an elevated frequency of chr 2 LOH relative to other chromosomal regions investigated in colonies derived from CFU-A and CFU-S obtained from repopulated bone marrow 120 days post-transplantation suggest that chr 2 LOH induced directly by irradiation may not be as high a frequency event in longterm repopulating stem cells as might be inferred from some of the cytogenetic studies.
Thus, whilst deletions involving one homologue of chromosome 2 can be directly induced in clonogenic stem cells by irradiation and it is tempting to speculate that radiationinduced chr 2 LOH is an initiating lesion for radiation-induced AML, evidence that these initial lesions are the lesions detected many months later in the fully evolved leukaemias is lacking. The high frequencies of translocations detected in cytogenetic studies, 17 the recognition that some radiationinduced aberrations are unstable with translocations preceding deletion 17 and the description of a terminal translocation evolving into an interstitial deletion in a radiation-induced AML 35 point to chromosomal instability contributing to the evolution of the leukaemias. In this respect, a transgenic model of acute promyelocytic leukaemia 40 might be instructive. In these transgenic mice the expression of the promyelocytic leukaemia (PML)-retinoic acid receptor (RAR␣) cDNA in myeloid cells produces a 100% incidence of a myeloproliferative disease, but only 15-20% of these mice develop acute leukaemia after a latency of 6-13 months. Co-expression of the RAR2␣-PML reciprocal fusion gene increased the probability of leukaemia development, but did not influence latency. More than 80% of these leukaemias exhibited interstitial or terminal deletions of one chr 2 homologue and spectral karyotyping revealed that leukaemic cells with chr 2 deletion generally exhibited additional abnormalities. The authors conclude that their data are consistent with a role for the RAR␣-PML translocation in promoting chr 2 deletions and chr 2 deletions predisposing to chromosomal instability. In this model, chr 2 deletions characterised the fully evolved leukaemias, but were not the initiating genetic lesion. Thus, on the basis of a variety of findings in mouse models, an important role for chr 2 deletion in the evolution of radiationinduced AML may be in the promotion of chromosomal instability, but lesions other than deletions may be important in initiating leukaemic transformation.
